Navigation Links
Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
Date:6/24/2009

Seventy-Seven Percent of Surveyed Physicians Will Increase Their Use of Carbapenems In the Next Five Years, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., June 24 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that availability in both intravenous and oral formulation is a leading drug attribute that surveyed physicians prefer for the treatment of complicated urinary tract infections (UTIs) in the hospital setting. Antibiotics available in interchangeable oral and parenteral formulations can facilitate step-down therapy and discharge from the hospital to the outpatient setting.

"Physicians prescribe a wide variety of antibiotics for UTIs, mainly from the quinolone and cephalosporin classes," stated Lisa Arias, analyst at Decision Resources. "These broad-spectrum agents are popular first-line agents in UTIs, and oral quinolones, in particular, have become a popular choice for first-line, step-down and discharge therapy."

The new report entitled Hospital Anti-Infectives Insight Series: Urinary Tract Infections also finds that extended-spectrum beta-lactamase-producing and quinolone-resistant gram-negative pathogens are among the most concerning pathogens, and that 77 percent of surveyed physicians expect to increase their prescribing of carbapenems for complicated UTIs in the next five years. These potent, broad-spectrum antibiotics are especially useful for treating gram-negative infections involving resistant organisms.

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Gisselle Morales
    Decision Resources
    781-296-2691
    gmorales@dresources.com

    Elizabeth Marshall
    Decision Resources, Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
2. LMS integrated obstetrics solution achieves general availability
3. Media availability: low-fat dietary pattern may lower risk of ovarian cancer
4. PA Breast Cancer Coalition Announces Special Press Availability for PA Breast Cancer Coalition Annual Conference
5. Pelosi to Hold Press Availability with SCHIP Family Tomorrow Morning
6. Wyeth Consumer Healthcare Announces the Availability of Centrum Cardio and New Formula Centrum Products
7. Anthem Blue Cross and Blue Shield in Kentucky Announces the Availability of New Health Plans for Medicare Beneficiaries
8. Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer
9. Visage Imaging Expands Availability of Its Advanced Visualization Offering
10. PharMEDium Announces Availability of Pre-Filled Operating Room Perioperative Compounded Drugs
11. Dblur Announces the Availability of a Software Lens(TM) Enabled Chip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... York, NY (PRWEB) , ... June 19, 2017 , ... ... this year, it’s going to be a humdinger. A warm winter and wet spring ... summer wedding guests. “No one wants to be swatting away pesky mosquitoes when a ...
(Date:6/19/2017)... , ... June 19, 2017 , ... ... designed to foster the international exchange of actionable insights to improve health ... discussing its mission to make clinical trial management faster, easier, and less painful. ...
(Date:6/19/2017)... ... June 19, 2017 , ... Intalere, the healthcare industry leader ... Show at its Elevate 2017 meeting in Orlando, Fla. The event featured diversity ... products and services to Intalere members. , “Intalere is dedicated to providing our ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/19/2017)... ... June 19, 2017 , ... Aeroflow Breastpumps announced their partnership ... insurance plans to families and individuals who qualify for government-sponsored programs such as ... for Molina members effective July 2017. , “We are delighted to partner ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... Israel , May 30, 2017 Therapix ... pharmaceutical Company specializing in the development of cannabinoid-based ... present a company overview at three upcoming scientific ... 7th Annual LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... , May 25, 2017  In response to the ... , Direct Relief is working with Pfizer to make ... at no cost to community health centers, free and ... nationwide. "Pfizer has a long-standing commitment ... and ensuring patient safety through educational activities," said ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, the ... announces the launch of a new website ... results of a clinical study that showed surprising ... with Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, ... that there are no other treatments that clear ...
Breaking Medicine Technology: